TY - JOUR
T1 - Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021
AU - Rothstein, Tanner E.
AU - Cunningham, Scott A.
AU - Rieke, Rachelle A.
AU - Mainella, Jill M.
AU - Mutchler, Melissa M.
AU - Patel, Robin
N1 - Funding Information:
Copyright © 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Robin Patel, patel.robin@mayo.edu. The authors declare a conflict of interest. Dr. Patel reports grants from Merck, ContraFect, TenNor Therapeutics Limited and Shionogi. Dr. Patel is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, and Qvella; monies are paid to Mayo Clinic. Dr. Patel is also a consultant to Netflix. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Scott A. Cunningham reports receiving an honorarium from the Antibacterial Resistance Leadership Group. Received 29 December 2021 Returned for modification 3 February 2022 Accepted 26 February 2022 Published 21 March 2022
Publisher Copyright:
© 2022 American Society for Microbiology. All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - The epidemiology of macrolide resistance in Mycoplasma (Mycoplasmoides) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
AB - The epidemiology of macrolide resistance in Mycoplasma (Mycoplasmoides) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
KW - Mycoplasma pneumoniae
KW - antibiotic resistance
KW - macrolides
KW - pneumonia
KW - surveillance studies
UR - http://www.scopus.com/inward/record.url?scp=85128448834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128448834&partnerID=8YFLogxK
U2 - 10.1128/aac.02432-21
DO - 10.1128/aac.02432-21
M3 - Article
C2 - 35311520
AN - SCOPUS:85128448834
SN - 0066-4804
VL - 66
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 4
ER -